<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37759738</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Does SARS-CoV-2 Induce IgG4 Synthesis to Evade the Immune System?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13091338</ELocationID><Abstract><AbstractText>SARS-CoV-2, the virus that causes the COVID-19 disease, has been shown to cause immune suppression in certain individuals. This can manifest as a reduced ability of the host's immune system to effectively control the infection. Studies have reported that patients with COVID-19 can exhibit a decline in white blood cell counts, including natural killer cells and T cells, which are integral components of the immune system's response to viral pathogens. These cells play critical roles in the immune response to viral infections, and their depletion can make it harder for the body to mount an effective defense against the virus. Additionally, the virus can also directly infect immune cells, further compromising their ability to function. Some individuals with severe COVID-19 pneumonia may develop a "cytokine storm", an overactive immune response that may result in tissue damage and organ malfunction. The underlying mechanisms of immune suppression in SARS-CoV-2 are not entirely understood at this time, and research is being conducted to gain a more comprehensive understanding. Research has shown that severe SARS-CoV-2 infection promotes the synthesis of IgG4 antibodies. In this study, we propose the hypothesis that IgG4 antibodies produced by B cells in response to infection by SARS-CoV-2 generate immunological tolerance, which prevents its elimination and leads to persistent and chronic infection. In summary, we believe that this constitutes another immune evasion mechanism that bears striking similarities to that developed by cancer cells to evade immune surveillance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubio-Casillas</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2978-5107</Identifier><AffiliationInfo><Affiliation>Autlan Regional Hospital, Health Secretariat, Autlan 48900, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Laboratory, Autlan Regional Preparatory School, University of Guadalajara, Autlan 48900, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redwan</LastName><ForeName>Elrashdy M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Biological Science Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, New Borg El-Arab 21934, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uversky</LastName><ForeName>Vladimir N</ForeName><Initials>VN</Initials><Identifier Source="ORCID">0000-0002-4037-5857</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgG4</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Tregs</Keyword><Keyword MajorTopicYN="N">immune tolerance</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37759738</ArticleId><ArticleId IdType="pmc">PMC10526126</ArticleId><ArticleId IdType="doi">10.3390/biom13091338</ArticleId><ArticleId IdType="pii">biom13091338</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Desimmie B.A., Raru Y.Y., Awadh H.M., He P., Teka S., Willenburg K.S. Insights into SARS-CoV-2 Persistence and Its Relevance. Viruses. 2021;13:1025. doi: 10.3390/v13061025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061025</ArticleId><ArticleId IdType="pmc">PMC8228265</ArticleId><ArticleId IdType="pubmed">34072390</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhang Y., Moorman J.P., Yao Z.Q., Jia Z.S. Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. Immunology. 2014;143:319&#x2013;330. doi: 10.1111/imm.12349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12349</ArticleId><ArticleId IdType="pmc">PMC4212946</ArticleId><ArticleId IdType="pubmed">24965611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani R., Zentilin L., Correa R., Colliva A., Silvestri F., Zacchigna S., Collesi C., Giacca M. Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19. J. Pathol. 2023;259:254&#x2013;263. doi: 10.1002/path.6035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.6035</ArticleId><ArticleId IdType="pmc">PMC10107739</ArticleId><ArticleId IdType="pubmed">36651103</ArticleId></ArticleIdList></Reference><Reference><Citation>Grey H.M., Kunkel H.G. H Chain Subgroups of Myeloma Proteins and Normal 7s Gamma-Globulin. J. Exp. Med. 1964;120:253&#x2013;266. doi: 10.1084/jem.120.2.253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.120.2.253</ArticleId><ArticleId IdType="pmc">PMC2137727</ArticleId><ArticleId IdType="pubmed">14206440</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry W.D., Fahey J.L. Subclasses of Human Gamma-2-Globulin Based on Differences in the Heavy Polypeptide Chains. Science. 1964;146:400&#x2013;401. doi: 10.1126/science.146.3642.400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.146.3642.400</ArticleId><ArticleId IdType="pubmed">14186462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayumi M., Kuritani T., Kubagawa H., Cooper M.D. IgG subclass expression by human B lymphocytes and plasma cells: B lymphocytes precommitted to IgG subclass can be preferentially induced by polyclonal mitogens with T cell help. J. Immunol. 1983;130:671&#x2013;677. doi: 10.4049/jimmunol.130.2.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.130.2.671</ArticleId><ArticleId IdType="pubmed">6217248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.E., Katsaounou P., et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992&#x2013;1000. doi: 10.1016/j.chom.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S., Gonzalez J., Edwards K., Mallajosyula V., Buzzanco A.S., Sherwood R., Buffone C., Kathale N., Providenza S., Xie M.M., et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat. Immunol. 2021;22:67&#x2013;73. doi: 10.1038/s41590-020-00828-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00828-7</ArticleId><ArticleId IdType="pmc">PMC8130642</ArticleId><ArticleId IdType="pubmed">33169014</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates J.L., Ehrbar D.J., Hunt D.T., Girardin R.C., Dupuis A.P., 2nd, Payne A.F., Sowizral M., Varney S., Kulas K.E., Demarest V.L., et al. Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Rep. Med. 2021;2:100329. doi: 10.1016/j.xcrm.2021.100329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100329</ArticleId><ArticleId IdType="pmc">PMC8205277</ArticleId><ArticleId IdType="pubmed">34151306</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky V.N., Redwan E.M., Makis W., Rubio-Casillas A. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines. 2023;11:991. doi: 10.3390/vaccines11050991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050991</ArticleId><ArticleId IdType="pmc">PMC10222767</ArticleId><ArticleId IdType="pubmed">37243095</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura A.D., da Costa H.H.M., Correa V.A., de Lima A.K., Lindoso J.A.L., De Gaspari E., Hong M.A., Cunha-Junior J.P., Prudencio C.R. Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Sci. Rep. 2021;11:17642. doi: 10.1038/s41598-021-95045-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95045-z</ArticleId><ArticleId IdType="pmc">PMC8417219</ArticleId><ArticleId IdType="pubmed">34480056</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H., Jia T., Chen J., Zeng S., Qiu Z., Wu S., Li X., Lei Y., Wang X., Wu W., et al. The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Front. Immunol. 2021;12:632814. doi: 10.3389/fimmu.2021.632814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.632814</ArticleId><ArticleId IdType="pmc">PMC7982848</ArticleId><ArticleId IdType="pubmed">33763078</ArticleId></ArticleIdList></Reference><Reference><Citation>Irrgang P., Gerling J., Kocher K., Lapuente D., Steininger P., Habenicht K., Wytopil M., Beileke S., Schafer S., Zhong J., et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2023;8:eade2798. doi: 10.1126/sciimmunol.ade2798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.ade2798</ArticleId><ArticleId IdType="pmc">PMC9847566</ArticleId><ArticleId IdType="pubmed">36548397</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E., Lanzillotta M., Strollo M., Ramirez G.A., Dagna L., Tresoldi M. Serum IgG4 level predicts COVID-19 related mortality. Eur. J. Intern. Med. 2021;93:107&#x2013;109. doi: 10.1016/j.ejim.2021.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.09.012</ArticleId><ArticleId IdType="pmc">PMC8461218</ArticleId><ArticleId IdType="pubmed">34598853</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E., Campochiaro C., Cavalli G., De Luca G., Napolitano A., La Marca S., Boffini N., Da Prat V., Di Terlizzi G., Lanzillotta M., et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Ann. Rheum. Dis. 2020;79:1277&#x2013;1285. doi: 10.1136/annrheumdis-2020-218122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218122</ArticleId><ArticleId IdType="pmc">PMC7509526</ArticleId><ArticleId IdType="pubmed">32620597</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E., Della-Torre F., Kusanovic M., Scotti R., Ramirez G.A., Dagna L., Tresoldi M. Treating COVID-19 with colchicine in community healthcare setting. Clin. Immunol. 2020;217:108490. doi: 10.1016/j.clim.2020.108490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108490</ArticleId><ArticleId IdType="pmc">PMC7261351</ArticleId><ArticleId IdType="pubmed">32492478</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E., Lanzillotta M., Campochiaro C., Cavalli G., De Luca G., Tomelleri A., Boffini N., De Lorenzo R., Ruggeri A., Rovere-Querini P., et al. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front. Immunol. 2021;12:675678. doi: 10.3389/fimmu.2021.675678.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.675678</ArticleId><ArticleId IdType="pmc">PMC8117339</ArticleId><ArticleId IdType="pubmed">33995419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Xia T., Shin W.J., Yu K.M., Jung W., Herrmann A., Foo S.S., Chen W., Zhang P., Lee J.S., et al. Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8. mBio. 2022;13:e0040222. doi: 10.1128/mbio.00402-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00402-22</ArticleId><ArticleId IdType="pmc">PMC9040823</ArticleId><ArticleId IdType="pubmed">35343786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolini J.N., Benson E.M. The role of human interleukin-6 in B-cell isotype regulation and differentiation. Cell Immunol. 1990;125:197&#x2013;209. doi: 10.1016/0008-8749(90)90074-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0008-8749(90)90074-2</ArticleId><ArticleId IdType="pubmed">2104575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano Y., Noma T., Kou K., Yoshizawa I., Yata J. Regulation of human IgG subclass production by cytokines: Human IgG subclass production enhanced differentially by interleukin-6. Immunology. 1995;84:278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1415106</ArticleId><ArticleId IdType="pubmed">7751005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulak N.A., Trzcinski R. Disguised aspects of IgG4. Eur. J. Intern. Med. 2022;95:97. doi: 10.1016/j.ejim.2021.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.10.016</ArticleId><ArticleId IdType="pmc">PMC8549607</ArticleId><ArticleId IdType="pubmed">34756504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirula A., Glaser S.M., Kalled S.L., Taylor F.R. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr. Opin. Rheumatol. 2011;23:119&#x2013;124. doi: 10.1097/BOR.0b013e3283412fd4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e3283412fd4</ArticleId><ArticleId IdType="pubmed">21124094</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne S.K., Burbelo P.D., Chetchotisakd P., Suputtamongkol Y., Kiertiburanakul S., Shaw P.A., Kirk J.L., Jutivorakool K., Zaman R., Ding L., et al. Adult-onset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 2012;367:725&#x2013;734. doi: 10.1056/NEJMoa1111160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1111160</ArticleId><ArticleId IdType="pmc">PMC4190026</ArticleId><ArticleId IdType="pubmed">22913682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Bolze A., Jouanguy E., Zhang S.Y., Effort C.H.G., Cobat A., Notarangelo L.D., Su H.C., Abel L., et al. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med. 2020;1:14&#x2013;20. doi: 10.1016/j.medj.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7748410</ArticleId><ArticleId IdType="pubmed">33363283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrestier R., Bastard P., Belmondo T., Voiriot G., Urbina T., Luyt C.E., Gervais A., Bizien L., Segaux L., Ben Ahmed M., et al. Auto-antibodies against type I IFNs in &gt;10% of critically ill COVID-19 patients: A prospective multicentre study. Ann. Intensive Care. 2022;12:121. doi: 10.1186/s13613-022-01095-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-022-01095-5</ArticleId><ArticleId IdType="pmc">PMC9803887</ArticleId><ArticleId IdType="pubmed">36586050</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D., Diaz A., Romero M., Mendez N.V., Landin A.M., Blomberg B.B. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. Immun Ageing. 2013;10:14. doi: 10.1186/1742-4933-10-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4933-10-14</ArticleId><ArticleId IdType="pmc">PMC3639840</ArticleId><ArticleId IdType="pubmed">23607926</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavacini L.A., Kuhrt D., Duval M., Mayer K., Posner M.R. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res. Hum. Retroviruses. 2003;19:785&#x2013;792. doi: 10.1089/088922203769232584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/088922203769232584</ArticleId><ArticleId IdType="pubmed">14585209</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthar M.S., Zimmerman M.G., Kauffman R.C., Mantus G., Linderman S.L., Hudson W.H., Vanderheiden A., Nyhoff L., Davis C.W., Adekunle O., et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep. Med. 2020;1:100040. doi: 10.1016/j.xcrm.2020.100040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100040</ArticleId><ArticleId IdType="pmc">PMC7276302</ArticleId><ArticleId IdType="pubmed">32835303</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L., Martinuzzi D., Hyseni I., Benincasa L., Molesti E., Casa E., Lapini G., Piu P., Trombetta C.M., Marchi S., et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J. Immunol. Methods. 2021;489:112937. doi: 10.1016/j.jim.2020.112937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2020.112937</ArticleId><ArticleId IdType="pmc">PMC7695554</ArticleId><ArticleId IdType="pubmed">33253698</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalberse R.C., Dieges P.H., Knul-Bretlova V., Vooren P., Aalbers M., van Leeuwen J. IgG4 as a blocking antibody. Clin. Rev. Allergy. 1983;1:289&#x2013;302. doi: 10.1007/BF02991163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02991163</ArticleId><ArticleId IdType="pubmed">6370405</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid Y. Regulatory T cells and infection: A dangerous necessity. Nat. Rev. Immunol. 2007;7:875&#x2013;888. doi: 10.1038/nri2189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2189</ArticleId><ArticleId IdType="pubmed">17948021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Casillas A., Redwan E.M., Uversky V.N. SARS-CoV-2: A master of immune evasion. Biomedicines. 2022;10:1339. doi: 10.3390/biomedicines10061339.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10061339</ArticleId><ArticleId IdType="pmc">PMC9220273</ArticleId><ArticleId IdType="pubmed">35740361</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoguina J.S., Weyand E., Larbi J., Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: Role of IL-10. J. Immunol. 2005;174:4718&#x2013;4726. doi: 10.4049/jimmunol.174.8.4718.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.8.4718</ArticleId><ArticleId IdType="pubmed">15814696</ArticleId></ArticleIdList></Reference><Reference><Citation>Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: Mechanisms of differentiation and function. Annu. Rev. Immunol. 2012;30:531&#x2013;564. doi: 10.1146/annurev.immunol.25.022106.141623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141623</ArticleId><ArticleId IdType="pmc">PMC6066374</ArticleId><ArticleId IdType="pubmed">22224781</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008;8:523&#x2013;532. doi: 10.1038/nri2343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2343</ArticleId><ArticleId IdType="pmc">PMC2665249</ArticleId><ArticleId IdType="pubmed">18566595</ArticleId></ArticleIdList></Reference><Reference><Citation>Panduro M., Benoist C., Mathis D. Tissue Tregs. Annu. Rev. Immunol. 2016;34:609&#x2013;633. doi: 10.1146/annurev-immunol-032712-095948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032712-095948</ArticleId><ArticleId IdType="pmc">PMC4942112</ArticleId><ArticleId IdType="pubmed">27168246</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simone M., Arrigoni A., Rossetti G., Gruarin P., Ranzani V., Politano C., Bonnal R.J.P., Provasi E., Sarnicola M.L., Panzeri I., et al. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity. 2016;45:1135&#x2013;1147. doi: 10.1016/j.immuni.2016.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.10.021</ArticleId><ArticleId IdType="pmc">PMC5119953</ArticleId><ArticleId IdType="pubmed">27851914</ArticleId></ArticleIdList></Reference><Reference><Citation>Plitas G., Konopacki C., Wu K., Bos P.D., Morrow M., Putintseva E.V., Chudakov D.M., Rudensky A.Y. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 2016;45:1122&#x2013;1134. doi: 10.1016/j.immuni.2016.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.10.032</ArticleId><ArticleId IdType="pmc">PMC5134901</ArticleId><ArticleId IdType="pubmed">27851913</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnuson A.M., Kiner E., Ergun A., Park J.S., Asinovski N., Ortiz-Lopez A., Kilcoyne A., Paoluzzi-Tomada E., Weissleder R., Mathis D., et al. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc. Natl. Acad. Sci. USA. 2018;115:E10672&#x2013;E10681. doi: 10.1073/pnas.1810580115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1810580115</ArticleId><ArticleId IdType="pmc">PMC6233093</ArticleId><ArticleId IdType="pubmed">30348759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund J.M., Hsing L., Pham T.T., Rudensky A.Y. Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008;320:1220&#x2013;1224. doi: 10.1126/science.1155209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1155209</ArticleId><ArticleId IdType="pmc">PMC2519146</ArticleId><ArticleId IdType="pubmed">18436744</ArticleId></ArticleIdList></Reference><Reference><Citation>Almanan M., Raynor J., Sholl A., Wang M., Chougnet C., Cardin R.D., Hildeman D.A. Tissue-specific control of latent CMV reactivation by regulatory T cells. PLoS Pathog. 2017;13:e1006507. doi: 10.1371/journal.ppat.1006507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006507</ArticleId><ArticleId IdType="pmc">PMC5552023</ArticleId><ArticleId IdType="pubmed">28796839</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan-Pena S., Leon J., Chowdhary K., Michelson D.A., Vijaykumar B., Yang L., Magnuson A.M., Chen F., Manickas-Hill Z., Piechocka-Trocha A., et al. Profound Treg perturbations correlate with COVID-19 severity. Proc. Natl. Acad. Sci. USA. 2021;118:e2111315118. doi: 10.1073/pnas.2111315118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111315118</ArticleId><ArticleId IdType="pmc">PMC8449354</ArticleId><ArticleId IdType="pubmed">34433692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagenstein J., Melderis S., Nosko A., Warkotsch M.T., Richter J.V., Ramcke T., Herrnstadt G.R., Scheller J., Yan I., Mittrucker H.W., et al. A Novel Role for IL-6 Receptor Classic Signaling: Induction of RORgammat(+)Foxp3(+) Tregs with Enhanced Suppressive Capacity. J. Am. Soc. Nephrol. 2019;30:1439&#x2013;1453. doi: 10.1681/ASN.2019020118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2019020118</ArticleId><ArticleId IdType="pmc">PMC6683717</ArticleId><ArticleId IdType="pubmed">31311828</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhont S., Derom E., Van Braeckel E., Depuydt P., Lambrecht B.N. The pathophysiology of &#x2018;happy&#x2019; hypoxemia in COVID-19. Respir. Res. 2020;21:198. doi: 10.1186/s12931-020-01462-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01462-5</ArticleId><ArticleId IdType="pmc">PMC7385717</ArticleId><ArticleId IdType="pubmed">32723327</ArticleId></ArticleIdList></Reference><Reference><Citation>Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P., Gimotty P.A., Gilks C.B., Lal P., Zhang L., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226&#x2013;230. doi: 10.1038/nature10169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10169</ArticleId><ArticleId IdType="pubmed">21753853</ArticleId></ArticleIdList></Reference><Reference><Citation>McElvaney O.J., McEvoy N.L., McElvaney O.F., Carroll T.P., Murphy M.P., Dunlea D.M., Ni Choileain O., Clarke J., O&#x2019;Connor E., Hogan G., et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am. J. Respir. Crit. Care Med. 2020;202:812&#x2013;821. doi: 10.1164/rccm.202005-1583OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202005-1583OC</ArticleId><ArticleId IdType="pmc">PMC7491404</ArticleId><ArticleId IdType="pubmed">32584597</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson M.J., Vignali P.D.A., Mullett S.J., Overacre-Delgoffe A.E., Peralta R.M., Grebinoski S., Menk A.V., Rittenhouse N.L., DePeaux K., Whetstone R.D., et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591:645&#x2013;651. doi: 10.1038/s41586-020-03045-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03045-2</ArticleId><ArticleId IdType="pmc">PMC7990682</ArticleId><ArticleId IdType="pubmed">33589820</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway C.A., Jr., Travers P., Walport M., Shlomchik M.J. Immunobiology: The Immune System in Health and Disease. 5th ed. Garland Science; New York, NY, USA: 2001. Pathogens have evolved various means of evading or subverting normal host defenses.</Citation></Reference><Reference><Citation>Rispens T., Meesters J., den Bleker T.H., Ooijevaar-De Heer P., Schuurman J., Parren P.W., Labrijn A., Aalberse R.C. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Mol. Immunol. 2013;53:35&#x2013;42. doi: 10.1016/j.molimm.2012.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2012.06.012</ArticleId><ArticleId IdType="pubmed">22784992</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L., Zhuang M.W., Deng J., Zheng Y., Zhang J., Nan M.L., Zhang X.J., Gao C., Wang P.H. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5&#x2013;MAVS, TLR3&#x2013;TRIF, and cGAS&#x2013;STING signaling pathways. J. Med. Virol. 2021;93:5376&#x2013;5389. doi: 10.1002/jmv.27050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27050</ArticleId><ArticleId IdType="pmc">PMC8242602</ArticleId><ArticleId IdType="pubmed">33913550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L., Ren L. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 2020;11:3810. doi: 10.1038/s41467-020-17665-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S.-J., Shin O.S. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways. J. Microbiol. 2022;60:290&#x2013;299. doi: 10.1007/s12275-022-1525-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12275-022-1525-1</ArticleId><ArticleId IdType="pmc">PMC8817151</ArticleId><ArticleId IdType="pubmed">35122601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid F., Dzakah E.E., Wang H., Tang S. The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta. Virus Res. 2021;296:198350. doi: 10.1016/j.virusres.2021.198350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198350</ArticleId><ArticleId IdType="pmc">PMC7897408</ArticleId><ArticleId IdType="pubmed">33626380</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Cao Z., Xie X., Zhang X., Chen J.Y.-C., Wang H., Menachery V.D., Rajsbaum R., Shi P.-Y. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 2020;33:108234. doi: 10.1016/j.celrep.2020.108234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo J.-S., Sasaki M., Cho S.X., Kasuga Y., Zhu B., Ouda R., Orba Y., de Figueiredo P., Sawa H., Kobayashi K.S. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nat. Commun. 2021;12:6602. doi: 10.1038/s41467-021-26910-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26910-8</ArticleId><ArticleId IdType="pmc">PMC8594428</ArticleId><ArticleId IdType="pubmed">34782627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen Y., Li Y., Huang F., Luo B., Yuan Y., Xia B., Ma X., Yang T., Yu F., et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Iota. Proc. Natl. Acad. Sci. USA. 2021;118:e2024202118. doi: 10.1073/pnas.2024202118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024202118</ArticleId><ArticleId IdType="pmc">PMC8201919</ArticleId><ArticleId IdType="pubmed">34021074</ArticleId></ArticleIdList></Reference><Reference><Citation>Merolli A., Kasaei L., Ramasamy S., Kolloli A., Kumar R., Subbian S., Feldman L.C. An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy. Sci. Rep. 2022;12:3794. doi: 10.1038/s41598-022-07867-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-07867-0</ArticleId><ArticleId IdType="pmc">PMC8904465</ArticleId><ArticleId IdType="pubmed">35260703</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepe A., Pietropaoli S., Vos M., Barba-Spaeth G., Zurzolo C. Tunneling nanotubes provide a route for SARS-CoV-2 spreading. Sci. Adv. 2022;8:eabo0171. doi: 10.1126/sciadv.abo0171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abo0171</ArticleId><ArticleId IdType="pmc">PMC9299553</ArticleId><ArticleId IdType="pubmed">35857849</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Abdullahi A., Ferreira I., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2013;714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P., Kemp S.A., Dhar M.S., Papa G., Meng B., Ferreira I., Datir R., Collier D.A., Albecka A., Singh S., et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114&#x2013;119. doi: 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A., Irie T., Suzuki R., Maemura T., Nasser H., Uriu K., Kosugi Y., Shirakawa K., Sadamasu K., Kimura I., et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022;602:300&#x2013;306. doi: 10.1038/s41586-021-04266-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04266-9</ArticleId><ArticleId IdType="pmc">PMC8828475</ArticleId><ArticleId IdType="pubmed">34823256</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannis P., Gilbert A.E., Josephs D.H., Ali N., Dodev T., Saul L., Correa I., Roberts L., Beddowes E., Koers A., et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J. Clin. Invest. 2013;123:1457&#x2013;1474. doi: 10.1172/JCI65579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI65579</ArticleId><ArticleId IdType="pmc">PMC3613918</ArticleId><ArticleId IdType="pubmed">23454746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Xu Q., Zhao C., Zhu Z., Zhu X., Zhou J., Zhang S., Yang T., Zhang B., Li J., et al. An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy. J. Immunother. Cancer. 2020;8:e000661. doi: 10.1136/jitc-2020-000661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-000661</ArticleId><ArticleId IdType="pmc">PMC7443307</ArticleId><ArticleId IdType="pubmed">32819973</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonas E., Alwi I., Pranata R., Huang I., Lim M.A., Yamin M., Nasution S.A., Setiati S., Virani S.S. Elevated interleukin levels are associated with higher severity and mortality in COVID 19&#x2013;a systematic review, meta-analysis, and meta-regression. Diabetes Metab. Syndr. 2020;14:2219&#x2013;2230. doi: 10.1016/j.dsx.2020.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.11.011</ArticleId><ArticleId IdType="pmc">PMC7669483</ArticleId><ArticleId IdType="pubmed">33395783</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Rong L., Cui R., Feng J., Jin Y., Yu Y., Chen X., Xu R. Dynamic changes in serum IL-6, IL-8, and IL-10 are associated with the outcome of patients with severe COVID-19 in ICU. Ann. Palliat. Med. 2020;10:3706&#x2013;3714. doi: 10.21037/apm-20-2134.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-20-2134</ArticleId><ArticleId IdType="pubmed">33615814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.-T., Juan C.-Y., Chang K.-J., Chen W.-J., Kuo M.-L. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis. 2001;22:1947&#x2013;1953. doi: 10.1093/carcin/22.12.1947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/22.12.1947</ArticleId><ArticleId IdType="pubmed">11751424</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>